Welcome to our dedicated page for Xencor news (Ticker: XNCR), a resource for investors and traders seeking the latest updates and insights on Xencor stock.
Xencor, Inc. (XNCR) is a leading clinical-stage biopharmaceutical company headquartered in the United States, dedicated to the discovery and development of engineered monoclonal antibody and protein therapeutics. The primary goal of Xencor is to address severe and life-threatening diseases that currently have unmet medical needs, such as autoimmune diseases, asthma, and various forms of cancer.
Xencor leverages its proprietary XmAb® technology platform to enhance the natural immune functions of antibodies while maintaining a high degree of similarity to natural antibodies (over 99.5% identity). This innovative approach allows Xencor to create biotherapeutics that are more potent, safer, and longer-lasting, thereby improving patient outcomes and quality of life.
One of the key strengths of Xencor's XmAb technology is its ability to dramatically augment the immune functions of antibodies. This has resulted in a robust pipeline of product candidates, including eight in human clinical trials. Notable candidates in clinical development include XmAb5871 and XmAb7195, with several others such as XmAb14045 and XmAb662 in the pre-clinical stage. These candidates are being developed both by Xencor and in collaboration with pharmaceutical partners.
Financially, Xencor generates revenue through research and development collaborations and the licensing of its internally developed drug candidates. This collaborative approach not only advances their pipeline but also brings in essential funding to support ongoing and future projects.
Recently, Xencor has made significant strides in expanding its partnerships and advancing its clinical trials. These developments are crucial as they bring the company closer to delivering breakthrough treatments that can transform patient care in various therapeutic areas.
Overall, Xencor, Inc. stands out in the biopharmaceutical industry for its innovative approach to antibody and protein engineering, with a mission to fundamentally improve the treatment of serious diseases and enhance the quality of life for patients around the world.
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company, will have its CEO Bassil Dahiyat present at the 41st Annual J.P. Morgan Healthcare Conference. The presentation is scheduled for January 11, 2023, at 3:45 p.m. PST. A live webcast will be accessible in the Investors section of Xencor's website, with a replay available for 30 days post-event. Xencor focuses on developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 clinical candidates and three marketed medicines through partnerships.
Xencor, Inc. (NASDAQ: XNCR) announced new clinical data from its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody for relapsed or refractory non-Hodgkin lymphomas, presented at the ASH Annual Meeting. The data indicated a well-tolerated safety profile, with a 52% overall response rate in patients with DLBCL or HGBCL, and 88% in follicular lymphoma. Adverse events included neutropenia and cytokine release syndrome. Xencor aims to develop plamotamab in various chemotherapy-free regimens, indicating a strategic focus on improving treatment outcomes for B-cell cancers.
Xencor, a clinical-stage biopharmaceutical company listed on NASDAQ under the symbol XNCR, announced participation in two upcoming investor conferences. The first is the Jefferies London Healthcare Conference on November 15, 2022, at 8:00 a.m. GMT, followed by the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 12:30 p.m. EST. Live webcasts will be accessible via the company’s website, with replays available for 30 days post-event. Xencor specializes in engineered antibodies and cytokines for cancer and autoimmune disease treatments.
Xencor, Inc. (NASDAQ:XNCR) presented initial data from the Phase 2 study of vudalimab, a bispecific antibody, targeting metastatic castration-resistant prostate cancer (mCRPC) at the Society for Immunotherapy of Cancer Annual Meeting in Boston. The study included nine patients, with three showing more than 50% PSA reductions. However, safety concerns led to a reduction in chemotherapy intensity for future cohorts. Xencor plans to explore alternative chemotherapy combinations and has multiple ongoing studies for vudalimab and other XmAb programs.
Xencor, Inc. (NASDAQ:XNCR) reported Q3 2022 results, showing $27.3 million in revenue, up from $19.7 million in Q3 2021. The net loss decreased to $32.8 million or $(0.55) per share, compared to $(0.69) in Q3 2021. Key highlights include promising results from the XmAb564 IL-2 cytokine study, demonstrating a 117-fold Treg expansion. Xencor anticipates ending 2022 with $575 million to $600 million in cash and expects to fund R&D through 2025. Additional updates on clinical programs are forthcoming.
Xencor announced positive topline results from the Phase 1a study of XmAb564, a novel therapy targeting regulatory T cells (Tregs) for autoimmune diseases. A 117-fold increase in CD25bright Tregs was observed at the highest dose, with sustained activity over three weeks. XmAb564 was well-tolerated, showing no serious adverse events, and the first patient has been dosed in a Phase 1b study for atopic dermatitis and psoriasis. Results will be discussed in a webcast today at 4:30 PM ET.
Xencor, Inc. (NASDAQ: XNCR) announced it will present clinical data from its Phase 1 study of plamotamab, a CD20 x CD3 bispecific antibody, at the ASH Annual Meeting on December 12, 2022. Plamotamab showed encouraging results in patients with relapsed non-Hodgkin’s lymphoma. The study indicated a 47.4% overall response rate (ORR) in patients with diffuse large B-cell lymphoma and a 100% ORR in those with follicular lymphoma. Despite common adverse events like cytokine release syndrome, the treatment was generally well tolerated. This marks a significant step in Xencor's development of targeted cancer therapies.
Xencor, Inc. (NASDAQ: XNCR) announced it will release its third quarter 2022 financial results on November 7, 2022, after market close. A conference call and webcast will follow at 4:30 p.m. ET to discuss the results and provide an update on corporate activities. Xencor is engaged in developing engineered antibodies and cytokines to treat cancer and autoimmune diseases, with over 20 candidates in clinical trials and three marketed medicines utilizing its XmAb® technology.
SpikImm's SPK001, a monoclonal antibody for COVID-19 prevention, has been awarded "national priority" status by the French government. In Phase 1 trials, it showed excellent tolerance among initial cohorts. Targeting immunocompromised patients, the drug could address a significant market need, with around 300,000 patients in France alone. SpikImm plans to advance to a Phase 2 trial by Q1 2023 and may seek early access approval in Q2 2023. The company has partnered with Xencor to enhance the antibody's efficacy.
Xencor, Inc. (NASDAQ:XNCR) announced seven poster presentations at the 37th Annual Meeting of the Society for Immunotherapy of Cancer from November 10-12, 2022, in Boston. Key highlights include data from a Phase 2 study of vudalimab, a PD-1 x CTLA-4 bispecific antibody, plus chemotherapy for metastatic castration-resistant prostate cancer (mCRPC). Other studies involve XmAb819 for renal cell carcinoma and various preclinical programs. The findings will enhance understanding of these treatments and their potential impact on cancer therapies.
FAQ
What is the current stock price of Xencor (XNCR)?
What is the market cap of Xencor (XNCR)?
What is Xencor, Inc.?
What is the XmAb technology?
What are some key products in Xencor's pipeline?
How does Xencor generate revenue?
Where is Xencor, Inc. based?
What diseases does Xencor target?
What makes Xencor's biotherapeutics unique?
Who are Xencor's partners?
What recent achievements has Xencor made?
What is the primary goal of Xencor?
